Year in Review #ACR22 Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies ⁦@RheumNow⁩ https://t.co/EPtOrjJqLd

Preview of what is sure to be discussed more in detail later.. MIRROR trial of MTX co-administration with pegloticase in treatment of gout. MTX co-administration improved control of gout, reduced infusion reactions @RheumNow #ACR22 https://t.co/r0MEq1rkgO

ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford #ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L

Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh

Year in review #ACR22 IVIG received FDA approval for dermatomyositis in 2022! @RheumNow

Year in Review #ACR22 IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo First approved Rx for inflammatory myositis ⁦@RheumNow⁩ https://t.co/T6qVTQQdTp

Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval! #ACR22 @RheumNow https://t.co/BfHZm4Kl49

• The Evidence Based Rheumatology Podcast

Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for RA+ vs RA- in 5 distinct hands MRI sequences. Question: what was the performance of the rheumatologist or radiologist? https://t.co/93aZKPlKsO Abstr#0242 #ACR22 @Rheumnow https://t.co/uk2c3gbAOT

• Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthriti…

Year in Review #ACR22 CAR T cells: deep depletion of CD19 leading to immune reset 5 patients with active SLE Normalizations of complements, dsDNA Drug free remission 3 will mild immune reconstitution symptoms, 1 received tocilizumab @RheumNow

Nice chart w/JAKs/TYKs by drug and by cytokine pathways In reality there is a fair bit of crossover and "selectives" aren't nearly as selective as this implies Helpful to add deucravacitinib to the list! Looking forward to upcoming plenary #RheumNow #ACR22 #YearInReview https://t.co/MERzpvrFB9

Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology, #ACR22 #ACRambassador https://t.co/Ij2D7YikjT

Day 1 #ACR22. Tips to avoid burnout: stretch your legs, a change in scenery for virtual attendees, replenish your sweets and savoury and importantly keep your furry friend happy 🐈‍⬛ #PetsAtACR @RheumNow #RheumPix https://t.co/opGVSjxLjE

#acr22 The Rise of JAK in rheumatology Look for Ab1117 in plenary 2 tomorrow for DEU and SLE @RheumNow https://t.co/nLpXGyrhfJ

Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1

GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5! @RheumNow #ACR22 #yearinreview #ACRBest